The use of thyroid-stimulating hormone-Edecrine pretreatment in the radioiodide therapy of metastatic thyroid cancer. Clinical tolerance and changes in the radioiodine kinetics.
D004338:Drug Combinations; D004361:Drug Tolerance; D004976:Ethacrynic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D006400:Hematocrit; D006801:Humans; D007022:Hypotension / Q000209:etiology; D007456:Iodine Isotopes / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D007700:Kinetics; D007958:Leukocyte Count; D009362:Neoplasm Metastasis; D013746:Tetany / Q000209:etiology; D013960:Thyroid Function Tests; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D013972:Thyrotropin / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D004338:Drug Combinations; D007456:Iodine Isotopes; D013972:Thyrotropin; D004976:Ethacrynic Acid